related documents
- A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma. Conferences
- A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors. Conferences
- A phase I/II clinical trial of veliparib (ABT-888) and radiation followed by maintenance therapy with veliparib and temozolomide in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG): A Pediatric Brain Tumor Consortium Interim Report of Phase I Study. Conferences
- A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. Conferences
- Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors. Conferences
- Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC) Conferences
- First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. Conferences
- Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). Conferences